PT - JOURNAL ARTICLE AU - Mollan, Katie R. AU - Eron, Joseph J. AU - Krajewski, Taylor J. AU - Painter, Wendy AU - Duke, Elizabeth R. AU - Morse, Caryn G. AU - Goecker, Erin A. AU - Premkumar, Lakshmanane AU - Wolfe, Cameron R. AU - Szewczyk, Laura J. AU - Alabanza, Paul L. AU - Loftis, Amy James AU - Degli-Angeli, Emily J. AU - Brown, Ariane J. AU - Dragavon, Joan A. AU - Won, John J. AU - Keys, Jessica AU - Hudgens, Michael G. AU - Wohl, David A. AU - Cohen, Myron S. AU - Baric, Ralph S. AU - Coombs, Robert W. AU - Sheahan, Timothy P. AU - Fischer, William A. TI - SARS-CoV-2 infectious virus, viral RNA in nasopharyngeal swabs, and serostatus of symptomatic COVID-19 outpatients in the United States AID - 10.1101/2021.05.28.21258011 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.28.21258011 4099 - http://medrxiv.org/content/early/2021/06/01/2021.05.28.21258011.short 4100 - http://medrxiv.org/content/early/2021/06/01/2021.05.28.21258011.full AB - Background SARS-CoV-2 infectious virus isolation in the upper airway of COVID-19 patients is associated with higher levels of viral RNA. However, comprehensive evaluation of the relationships between host and disease factors and infectious, replication competent virus is needed.Methods Symptomatic COVID-19 outpatients were enrolled from the United States. Clinical symptoms were recorded via patient diary. Nasopharyngeal swabs were collected to quantitate SARS-CoV-2 RNA by reverse transcriptase polymerase chain reaction and for infectious virus isolation in Vero E6-cells. SARS-CoV-2 antibodies were measured in serum using a validated ELISA assay.Findings Among 204 participants within one week of reported symptom onset (median=5, IQR 4-5 days), median age was 40 (min-max: 18-82 years), median nasopharyngeal viral RNA was 6.5 (IQR 4.7-7.6 log10 copies/mL), and 26% had detectable SARS-CoV-2 antibodies at baseline. Infectious virus was recovered in 7% of participants with antibodies compared to 58% of participants without antibodies (probability ratio (PR)=0.12, 95% CI: 0.04, 0.36; p=0.00016). Infectious virus isolation was also associated with higher levels of viral RNA (mean RNA difference +2.6 log10, 95% CI: 2.2, 3.0; p<0.0001) and fewer days since symptom onset (PR=0.79, 95% CI: 0.71, 0.88 per day; p<0.0001).Interpretation The presence of SARS-CoV-2 antibodies is strongly associated with clearance of infectious virus isolation. Seropositivity and viral RNA are likely more reliable markers of infectious virus suppression than subjective measure of COVID-19 symptoms. Virus-targeted treatment and prevention strategies should be administered as early as possible and ideally before seroconversion.Funding Ridgeback Biotherapeutics, LP and NIHClinicalTrials.gov Identifier NCT04405570Evidence before this study A deeper understanding of the viral and host factors associated with infectious virus detection is essential to accurately identify and quarantine contagious individuals. Several studies have reported associations between SARS-CoV-2 virus isolation and viral RNA levels or time from symptom onset. However, little is known about which host factors (i.e. demographics, comorbidities, SARS-CoV-2 seropositivity, symptomatology etc.) are associated with infectious virus detection. A search of PubMed on 12 April 2021 using keywords “COVID-19” or “SARS-CoV-2” and “infectious virus isolation” yielded 14 publications that evaluated virus isolation from respiratory samples of SARS-CoV-2 infected individuals. Five of these studies were case reports or case series that included up to 5 individuals. Seven studies included cohorts of both outpatients and hospitalized individuals and found strong associations between virus isolation and time from symptom onset and viral RNA level. Of these seven, only two studies evaluated the association between SARS-CoV-2-specific antibodies and virus isolation, but were limited by the late timing of collection (>10 days after symptom onset) or the small number of participants included. The remaining two articles compared virus isolation with antigen and molecular based diagnostics and reviewed prior literature respectively. Collectively, these studies suggest that infectious virus isolation from nasopharyngeal swab samples is possible up to 10 days from symptom onset in individuals with mild disease and for longer in those with severe illness or an underlying immune deficiency. No study has systematically evaluated host, disease, and viral factors associated with infectious virus isolation in the same cohort.Added value of this study To better understand the host, disease, and viral factors associated with virus isolation in ambulatory individuals with COVID-19, we analyzed demographic, symptom, virologic, and SARS-CoV-2-specific antibody data at baseline entry to outpatient care from 204 individuals enrolled in a randomized placebo-controlled study of a novel oral therapeutic. Host characteristics were self-reported and viral RNA quantitation, virus isolation, and SARS-2 specific antibody testing (IgG, IgM, IgA and total Ig) were performed at central laboratories. This represents the largest evaluation of virus isolation from symptomatic outpatients with COVID-19 reported to date, and affords an important opportunity to understand which host, virus, and disease factors are associated with the presence and clearance of infectious virus in the nasopharynx. Consistent with prior studies, we found that isolation of replication competent SARS-CoV-2 in vitro strongly correlated with both higher nasal viral qRT-PCR RNA levels and shorter time since symptom onset. Importantly, we also found that SARS-CoV-2 antibodies are strongly associated with the clearance of infectious virus, with virus isolation in 7% of seropositive individuals compared to 58% of seronegative individuals.Implications of all the available evidence Our findings provide a comprehensive analysis of key virus, host, and disease factors associated with infectious virus isolation and suggest that antibody detection appears to be a more reliable marker of infectious virus clearance than patient-reported symptom duration.Competing Interest StatementGrants or contracts were awarded to the participating sites from Ridgeback Biotherapeutics LP. KRM, CGM, and RSB have collaborations, unrelated to this study, with Gilead Sciences. JJE receives consulting honoraria outside the current study from Merck, VIR/GSK, and is a DSMB member for Adagio. WP and LJS are employed by Ridgeback Biotherapeutics LP. CGM has collaborations, unrelated to this study, with Roche, Moderna, Johnson & Johnson, Covis Pharma, and Chimerix. DAW has collaborations (advisory boards, consultancy, research funding), unrelated to this work, with Gilead Sciences. RSB has collaborations, unrelated to this study, with Moderna, Pfizer, Takeda, Eli Lily, and VaxArt. CRW has, unrelated to this study, financial disclosures for DSMB work with Biogen, Janssen, Merck and Atea, consultancy paid by Enzychem Lifesciences, and honoraria paid by Abbott Laboratories. TPS has contracts, unrelated to this work, from ViiV Healthcare and GSK. WAF has research funding from Ridgeback Biotherapeutics LP, participates on adjudication committees for Janssen, Syneos, and provides consultancy to Roche and Merck. All remaining authors have no conflicts of interest.Clinical TrialNCT04405570Funding StatementRidgeback Biotherapeutics LP funded this study and has subsequently entered into a collaboration with Merck to jointly develop molnupiravir. This research was also supported by the UNC-CH Center for AIDS Research P30 AI050410 (NIH); T32 ES007018 (NIEHS for TJK); a generous gift from the Chan Zuckerberg Initiative to RSB; FHCRC/UW CFAR AI-027757 and AI-106701 to RWC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by Western IRB (WIRB), and for each site by WIRB or a local IRB per site requirements.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUpon approval from the corresponding authors and Ridgeback Biotherapeutics, de-identified participant level data may be shared given the investigator who requests the data has approval from an Institutional Review Board, Independent Ethics Committee, or Research Ethics Board, as applicable, and executes a data use/sharing agreement.